Transgelins, cytoskeletal proteins implicated in different aspects of cancer development

Expert Review of Proteomics

Volumn 11, Issue 2, 2014, Pages 149-165

  Dvorakova, Monika ^a,b   Nenutil, Rudolf ^a   Bouchal, Pavel ^a,b  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

cancer; cytoskeleton; differentiation; proliferation; transgelin; transgelin 2

Indexed keywords

ACTIN; BETA CATENIN; KRUPPEL LIKE FACTOR 4; TRANSGELIN; TRANSGELIN 2; TRANSGELIN 3; TUMOR MARKER; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CYTOSKELETON PROTEIN; MUSCLE PROTEIN; TRANSGELIN 2 PROTEIN, HUMAN;

ACTIN FILAMENT; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; ENDOMETRIUM CANCER; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; ESOPHAGUS CANCER; GENE EXPRESSION REGULATION; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; METASTASIS; NEURITE; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SMOOTH MUSCLE FIBER; STOMACH CANCER; STROMA CELL; TUMOR CELL; TUMOR INVASION; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; CANCER STEM CELL; CELL AGING; CELL MOTION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROTEOMICS; SMOOTH MUSCLE;

ACTINS; APOPTOSIS; CARCINOGENESIS; CELL AGING; CELL MOVEMENT; CYTOSKELETAL PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; NEOPLASMS; NEOPLASTIC STEM CELLS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84896912045     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.860358     Document Type: Review

References (120)

1. Lees-Miller JP, Heeley DH, Smillie LB, Kay CM. Isolation and characterization of an abundant and novel 22-kDa protein (SM22) from chicken gizzard smooth muscle. J. Biol. Chem. 262(7), 2988-2993 (1987).
2. Shapland C, Lowings P, Lawson D. Identification of new actin-associated polypeptides that are modified by viral transformation and changes in cell shape. J. Cell Biol. 107(1), 153-161 (1988).
3. Murano S, Thweatt R, Shmookler Reis RJ, Jones RA, Moerman EJ, Goldstein S. Diverse gene sequences are overexpressed in werner syndrome fibroblasts undergoing premature replicative senescence. Mol. Cell. Biol. 11(8), 3905-3914 (1991).
4. Lawson D, Harrison M, Shapland C. Fibroblast transgelin and smooth muscle SM22alpha are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil. Cytoskeleton. 38(3), 250-257 (1997).
5. Shapland C, Hsuan JJ, Totty NF, Lawson D. Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein. J. Cell Biol. 121(5), 1065-1073 (1993).
6. Shields JM, Rogers-Graham K, Der CJ. Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J. Biol. Chem. 277(12), 9790-9799 (2002).
7. Peng J, Zhang Q, Ma Y et al. A rat-to-human search for proteomic alterations reveals transgelin as a biomarker relevant to colorectal carcinogenesis and liver metastasis. lectrophoresis 30(17), 2976-2987 (2009).
8. Yeo M, Kim D-K, Park HJ et al. Loss of transgelin in repeated bouts of ulcerative colitis-induced colon carcinogenesis. Proteomics 6(4), 1158-1165 (2006).
9. Zhao L, Wang H, Deng Y-J et al. Transgelin as a suppressor is associated with poor prognosis in colorectal carcinoma patients. Mod. Pathol. 22(6), 786-796 (2009).
10. Yeo M, Park HJ, Kim D-K et al. Loss of SM22 is a characteristic signature of colon carcinogenesis and its restoration suppresses colon tumorigenicity in vivo and in vitro. Cancer 116(11), 2581-2589 (2010).
11. Li S-Y, An P, Cai H-Y et al. Proteomic analysis of differentially expressed proteins involving in liver metastasis of human colorectal carcinoma. HBPD INT 9(2), 149-153 (2010).
12. Huang Q, Huang Q, Chen W et al. Identification of transgelin as a potential novel biomarker for gastric adenocarcinoma based on proteomics technology. J. Cancer Res. Clin. Oncol. 134(11), 1219-1227 (2008).
13. Ryu J-W, Kim H-J, Lee Y-S et al. The proteomics approach to find biomarkers in gastric cancer. J. Korean Med. Sci. 18(4), 505-509 (2003).
14. Li N, Zhang J, Liang Y et al. A controversial tumor marker: is SM22 a proper biomarker for gastric cancer cells? J. Proteome Res. 6(8), 3304-3312 (2007).
15. Sitek B, Luttges J, Marcus K et al. Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics 5(10), 2665-2679 (2005).
16. Mikuriya K, Kuramitsu Y, Ryozawa S et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int. J. Oncol. 30(4), 849-855 (2007).
17. Zhang J, Wang K, Zhang J, Liu SS, Dai L, Zhang J-Y. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J. Proteome Res. 10(6), 2863-2872 (2011).
18. Qi Y, Chiu J-F, Wang L, Kwong DLW, He Q-Y. Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics 5(11), 2960-2971 (2005).
19. Harada T, Kuramitsu Y, Makino A et al. Expression of tropomyosin alpha 4 chain is increased in esophageal squamous cell carcinoma as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Proteomics Clin. Appl. 1(2), 215-223 (2007).
20. Prasad PD, Stanton J-AL, Assinder SJ. Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer. Cell Tissue Res. 339(2), 337-347 (2010).
21. Chen R, Feng C, Xu Y. Cyclin-dependent kinase-associated protein Cks2 is associated with bladder cancer progression. J. Int. Med. Res. 39(2), 533-540 (2011).
22. Kawakami K, Enokida H, Tachiwada T et al. Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling. Oncol. Rep. 16(3), 521-531 (2006).
23. DeSouza L, Diehl G, Rodrigues MJ et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 4(2), 377-386 (2005).
24. Li LS, Kim H, Rhee H et al. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics 4(11), 3394-3400 (2004).
25. Klade CS, Voss T, Krystek E et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1(7), 890-898 (2001).
26. Assinder SJ, Stanton J-AL, Prasad PD. Transgelin: an actin-binding protein and tumour suppressor. Int. J. Biochem. Cell Biol. 41(3), 482-486 (2009).
27. Mori K, Muto Y, Kokuzawa J et al. Neuronal protein NP25 interacts with F-actin. Neurosci. Res. 48(4), 439-446 (2004).
28. Zhang JCL, Helmke BP, Shum A et al. SM22beta encodes a lineage-restricted cytoskeletal protein with a unique developmentally regulated pattern of expression. Mech. Dev. 115(1-2), 161-166 (2002).
29. Ren WZ, Ng GY, Wang RX et al. The identification of NP25: a novel protein that is differentially expressed by neuronal subpopulations. Brain Res. Mol. Brain Res. 22(1-4), 173-185 (1994).
30. Zhang Y, Ye Y, Shen D et al. Identification of transgelin-2 as a biomarker of colorectal cancer by laser capture microdissection and quantitative proteome analysis. Cancer Sci. 101(2), 523-529 (2010).
31. Shi Y-Y, Wang H-C, Yin Y-H et al. Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br. J. Cancer. 92(5), 929-934 (2005).
32. Hill JJ, Tremblay T-L, Pen A et al. Identification of vascular breast tumor markers by laser capture microdissection and label-free LC-MS. J. Proteome Res. 10(5), 2479-2493 (2011).
33. Rho J-H, Roehrl MHA, Wang JY. Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. J. Proteome Res. 8(12), 5610-5618 (2009).
34. Depaz IM, Wilce PA. The novel cytoskeleton-associated protein Neuronal protein 22: elevated expression in the developing rat brain. Brain Res. 1081(1), 59-64 (2006).
35. Pape M, Doxakis E, Reiff T et al. A function for the calponin family member NP25 in neurite outgrowth. Dev. Biol. 321(2), 434-443 (2008).
36. Fan L, Jaquet V, Dodd PR, Chen W, Wilce PA. Molecular cloning and characterization of hNP22: a gene up-regulated in human alcoholic brain. J. Neurochem. 76(5), 1275-1281 (2001).
37. Ito M, Depaz I, Wilce P, Suzuki T, Niwa S, Matsumoto I. Expression of human neuronal protein 22, a novel cytoskeleton-associated protein, was decreased in the anterior cingulate cortex of schizophrenia. Neurosci. Lett. 378(3), 125-130 (2005).
38. Almendral JM, Santaren JF, Perera J, Zerial M, Bravo R. Expression, cloning and cDNA sequence of a fibroblast serum-regulated gene encoding a putative actin-associated protein (p27). Exp. Cell Res. 181(2), 518-530 (1989).
39. Goodman A, Goode BL, Matsudaira P, Fink GR. The Saccharomyces cerevisiae calponin/transgelin homolog Scp1 functions with fimbrin to regulate stability and organization of the actin cytoskeleton. Mol. Biol. Cell. 14(7), 2617-2629 (2003).
40. Li M, Li S, Lou Z et al. Crystal structure of human transgelin. J. Struct. Biol. 162(2), 229-236 (2008).
41. Fu Y, Liu HW, Forsythe SM et al. Mutagenesis analysis of human SM22: characterization of actin binding. J. Appl. Physiol. 89(5), 1985-1990 (2000).
42. Han M, Dong L-H, Zheng B, Shi J-H, Wen J-K, Cheng Y. Smooth muscle alpha maintains the differentiated phenotype of vascular smooth muscle cells by inducing filamentous actin bundling. Life Sci. 84(13-14), 394-401 (2009).
43. Gimona M, Mital R. The single CH domain of calponin is neither sufficient nor necessary for F-actin binding. J. Cell. Sci. (Pt 13) 1813-1821 (1998)
44. Galkin VE, Orlova A, Fattoum A, Walsh MP, Egelman EH. The CH-domain of calponin does not determine the modes of calponin binding to F-actin. J. Mol. Biol. 359(2), 478-485 (2006).
45. Hayashi I, Ikura M. Crystal structure of the amino-terminal microtubule-binding domain of end-binding protein 1 (EB1). J. Biol. Chem. 278(38), 36430-36434 (2003).
46. Camoretti-Mercado B, Forsythe SM, Le Beau MM et al. Expression and cytogenetic localization of the human SM22 gene (TAGLN). Genomics 49(3), 452-457 (1998).
47. Li L, Miano JM, Cserjesi P, Olson EN. SM22 alpha, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis. Circ. Res. 78(2), 188-195 (1996).
48. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84(3), 767-801 (2004).
49. Mack CP. Signaling mechanisms that regulate smooth muscle cell differentiation. Arterioscler. Thromb. Vasc. Biol. 31(7), 1495-1505 (2011).
50. Qiu P, Feng XH, Li L. Interaction of Smad3 and SRF-associated complex mediates TGF-beta 1 signals to regulate SM22 transcription during myofibroblast differentiation. J. Mol. Cell. Cardiol. 35(12), 1407-1420 (2003).
51. Chen S, Kulik M, Lechleider RJ. Smad proteins regulate transcriptional induction of the SM22alpha gene by TGF-beta. Nucleic Acids Res. 31(4), 1302-1310 (2003).
52. Liu HW, Halayko AJ, Fernandes DJ et al. The RhoA/Rho kinase pathway regulates nuclear localization of serum response factor. Am. J. Respir. Cell Mol. Biol. 29(1), 39-47 (2003).
53. Mack CP, Somlyo AV, Hautmann M, Somlyo AP, Owens GK. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J. Biol. Chem. 276(1), 341-347 (2001).
54. Chen S, Crawford M, Day RM et al. RhoA modulates Smad signaling during transforming growth factor-beta-induced smooth muscle differentiation. J. Biol. Chem. 281(3), 1765-1770 (2006).
55. Adam PJ, Regan CP, Hautmann MB, Owens GK. Positive- and negative-acting Kruppel-like transcription factors bind a transforming growth factor beta control element required for expression of the smooth muscle cell differentiation marker SM22alpha in vivo. J. Biol. Chem. 275(48), 37798-37806 (2000).
56. Solway J, Seltzer J, Samaha FF et al. Structure and expression of a smooth muscle cell-specific gene, SM22 alpha. J. Biol. Chem. 270(22), 13460-13469 (1995).
57. Li L, Liu Z, Mercer B, Overbeek P, Olson EN. Evidence for serum response factor-mediated regulatory networks governing SM22alpha transcription in smooth, skeletal, and cardiac muscle cells. Dev. Biol. 187(2), 311-321 (1997).
58. Wang D, Chang PS, Wang Z et al. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell 105(7), 851-862 (2001).
59. Yoshida T, Sinha S, Dandre F et al. Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. Circ. Res. 92(8), 856-864 (2003).
60. Wang D-Z, Li S, Hockemeyer D et al. Potentiation of serum response factor activity by a family of myocardin-related transcription factors. Proc. Natl Acad. Sci. USA 99(23), 14855-14860 (2002).
61. Qiu P, Ritchie RP, Fu Z et al. Myocardin enhances Smad3-mediated transforming growth factor-beta1 signaling in a CArG box-independent manner: Smad-binding element is an important cis element for SM22alpha transcription in vivo. Circ. Res. 97(10), 983-991 (2005).
62. Hinson JS, Medlin MD, Lockman K, Taylor JM, Mack CP. Smooth muscle cell-specific transcription is regulated by nuclear localization of the myocardin-related transcription factors. Am. J. Physiol. Heart Circ. Physiol. 292(2), H1170-1180 (2007).
63. Miralles F, Posern G, Zaromytidou A-I, Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 113(3), 329-342 (2003).
64. Shafer SL, Towler DA. Transcriptional regulation of SM22alpha by Wnt3a: convergence with TGFbeta(1)/Smad signaling at a novel regulatory element. J. Mol. Cell. Cardiol. 46(5), 621-635 (2009).
65. Kaplan-Albuquerque N, Garat C, Van Putten V, Nemenoff RA. Regulation of SM22 alpha expression by arginine vasopressin and PDGF-BB in vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 285(4), H1444-1452 (2003).
66. Wang Z, Wang D-Z, Hockemeyer D, McAnally J, Nordheim A, Olson EN. Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature 428(6979), 185-189 (2004).
67. Taurin S, Sandbo N, Yau DM, Sethakorn N, Kach J, Dulin NO. Phosphorylation of myocardin by extracellular signal-regulated kinase. J. Biol. Chem. 284(49), 33789-33794 (2009).
68. Doi H, Iso T, Yamazaki M et al. HERP1 inhibits myocardin-induced vascular smooth muscle cell differentiation by interfering with SRF binding to CArG box. Arterioscler. Thromb. Vasc. Biol. 25(11), 2328-2334 (2005).
69. Yamamura H, Masuda H, Ikeda W et al. Structure and expression of the human SM22alpha gene, assignment of the gene to chromosome 11, and repression of the promoter activity by cytosine DNA methylation. J. Biochem. 122(1), 157-167 (1997).
70. Feil S, Hofmann F, Feil R. SM22alpha modulates vascular smooth muscle cell phenotype during atherogenesis. Circ. Res. 94(7), 863-865 (2004).
71. Zhang JC, Kim S, Helmke BP et al. Analysis of SM22alpha-deficient mice reveals unanticipated insights into smooth muscle cell differentiation and function. Mol. Cell. Biol. 21(4), 1336-1344 (2001).
72. Zeidan A, Sward K, Nordstrom I et al. Ablation of SM22alpha decreases contractility and actin contents of mouse vascular smooth muscle. FEBS Lett. 562(1-3), 141-146 (2004).
73. Je HD, Sohn UD. SM22alpha is required for agonist-induced regulation of contractility: evidence from SM22alpha knockout mice. Mol. Cells. 23(2), 175-181 (2007).
74. Gunst SJ, Zhang W. Actin cytoskeletal dynamics in smooth muscle: a new paradigm for the regulation of smooth muscle contraction. Am. J. Physiol. Cell Physiol. 295(3), C576-C587 (2008).
75. Zhang R, Zhou L, Li Q, Liu J, Yao W, Wan H. Up-regulation of two actin-associated proteins prompts pulmonary artery smooth muscle cell migration under hypoxia. Am. J. Respir. Cell. Mol. Biol. 41(4), 467-475 (2009).
76. Gimona M, Kaverina I, Resch GP, Vignal E, Burgstaller G. Calponin repeats regulate actin filament stability and formation of podosomes in smooth muscle cells. Mol. Biol. Cell 14(6), 2482-2491 (2003).
77. Kaverina I, Stradal TEB, Gimona M. Podosome formation in cultured A7r5 vascular smooth muscle cells requires Arp2/3-dependent de-novo actin polymerization at discrete microdomains. J. Cell. Sci. 116(Pt 24), 4915-4924 (2003).
78. Untergasser G, Gander R, Lilg C, Lepperdinger G, Plas E, Berger P. Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech. Ageing Dev. 126(1), 59-69 (2005).
79. Marshall CB, Krofft RD, Blonski MJ et al. Role of smooth muscle protein SM22a in glomerular epithelial cell injury. Am. J. Physiol. Renal Physiol. 300(4), F1026-F1042 (2011).
80. Page MJ, Amess B, Townsend RR et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc. Natl Acad. Sci. USA 96(22), 12589-12594 (1999).
81. Yu H, Ko?nigshoff M, Jayachandran A et al. Transgelin is a direct target of TGF-beta/ Smad3-dependent epithelial cell migration in lung fibrosis. FASEB J. 22(6), 1778-1789 (2008).
82. Pellegrin S, Mellor H. Actin stress fibres. J. Cell. Sci. 120(Pt 20), 3491-3499 (2007).
83. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell. Biol. 3(5), 349-363 (2002).
84. Huang J, Sheng H-H, Shen T et al. Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma. FEBS Lett. 580(15), 3571-3581 (2006).
85. Chen X-L, Zhou L, Yang J, Shen F-K, Zhao S-P, Wang Y-L. Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS. Mol. Med. Report 3(4), 589-596 (2010).
86. Fukushima C, Murakami A, Yoshitomi K et al. Comparative proteomic profiling in squamous cell carcinoma of the uterine cervix. Proteomics Clin. Appl. 5(3-4), 133-140 (2011).
87. Nohata N, Hanazawa T, Kikkawa N et al. Identification of novel molecular targets regulated by tumor suppressive miR-1/miR- 133a in maxillary sinus squamous cell carcinoma. Int. J. Oncol. 39(5), 1099-1107 (2011).
88. Yoshino H, Chiyomaru T, Enokida H et al. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br. J. Cancer. 104(5), 808-818 (2011).
89. Lin Y, Buckhaults PJ, Lee JR et al. Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer. Neoplasia 11(9), 864-873 (2009).
90. Zhang J, Song M-Q, Zhu J-S et al. Identification of differentially- expressed proteins between early submucosal non-invasive and invasive colorectal cancer using 2D-DIGE and mass spectrometry. Int. J. Immunopathol. Pharmacol. 24(4), 849-859 (2011).
91. Pang J, Liu W-P, Liu X-P et al. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J. Proteome Res. 9(1), 216-226 (2010).
92. Lee E-K, Han G-Y, Park HW, Song Y-J, Kim C-W. Transgelin promotes migration and invasion of cancer stem cells. J. Proteome Res. 9(10), 5108-5117 (2010).
93. Ami Y, Shimazui T, Akaza H et al. Gene expression profiles correlate with the morphology and metastasis characteristics of renal cell carcinoma cells. Oncol. Rep. 13(1), 75-80 (2005).
94. Xu S-G, Yan P-J, Shao Z-M. Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis. J. Cancer Res. Clin. Oncol. 136(10), 1545-1556 (2010).
95. Kim H-J, Kang U-B, Lee H et al. Profiling of differentially expressed proteins in stage IV colorectal cancers with good and poor outcomes. J. Proteomics 75(10), 2983-2997 (2012).
96. Massague J. TGFbeta in Cancer. Cell 134(2), 215-230 (2008).
97. Grusch M, Petz M, Metzner T, Oztu?rk D, Schneller D, Mikulits W. The crosstalk of RAS with the TGF-b family during carcinoma progression and its implications for targeted cancer therapy. Curr. Cancer Drug Targets 10(8), 849-857 (2010).
98. Zavadil J, Bo?ttinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24(37), 5764-5774 (2005).
99. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
100. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer. 123(10), 2229-2238 (2008).
101. Yu B, Chen X, Li J et al. Stromal fibroblasts in the microenvironment of gastric carcinomas promote tumor metastasis via upregulating TAGLN expression. BMC Cell Biol. 14, 17 (2013).
102. Yang Z, Chang Y-J, Miyamoto H et al. Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol. Endocrinol. 21(2), 343-358 (2007).
103. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev. 28(1-2), 5-14 (2009).
104. Thompson O, Moghraby JS, Ayscough KR, Winder SJ. Depletion of the actin bundling protein SM22/transgelin increases actin dynamics and enhances the tumourigenic phenotypes of cells. BMC Cell Biol. 13, 1 (2012).
105. Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning model. J. Cell Biol. 188(1), 11-19 (2010).
106. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett. 582(14), 2093-2101 (2008).
107. Nair RR, Solway J, Boyd DD. Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression. J. Biol. Chem. 281(36), 26424-26436 (2006).
108. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8(9), 729-740 (2007).
109. Gourlay CW, Carpp LN, Timpson P, Winder SJ, Ayscough KR. A role for the actin cytoskeleton in cell death and aging in yeast. J. Cell Biol. 164(6), 803-809 (2004).
110. Kato Y, Salumbides BC, Wang X-F et al. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol. Cancer Ther. 6(1), 70-81 (2007).
111. Kim TR, Moon JH, Lee HM, Cho EW, Paik SG, Kim IG. SM22alpha inhibits cell proliferation and protects against anticancer drugs and gamma-radiation in HepG2 cells: involvement of metallothioneins. FEBS Lett. 583(20), 3356-3362 (2009).
112. Kim TR, Lee HM, Lee SY et al. SM22a-induced activation of p16INK4a/ retinoblastoma pathway promotes cellular senescence caused by a subclinical dose of g-radiation and doxorubicin in HepG2 cells. Biochem. Biophys. Res. Commun. 400(1), 100-105 (2010).
113. Kim TR, Cho EW, Paik SG, Kim IG. Hypoxia-induced SM22a in A549 cells activates the IGF1R/PI3K/Akt pathway, conferring cellular resistance against chemoand radiation therapy. FEBS Lett. 586(4), 303-309 (2012).
114. Campisi J. Cellular senescence: putting the paradoxes in perspective. Curr. Opin. Genet. Dev. 21(1), 107-112 (2011).
115. Castro P, Giri D, Lamb D, Ittmann M. Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 55(1), 30-38 (2003).
116. Davalos AR, Coppe J-P, Campisi J, Desprez P-Y. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 29(2), 273-283 (2010).
117. Chen J, Watanabe M, Huang P et al. REIC/Dkk-3 stable transfection reduces the malignant phenotype of mouse prostate cancer RM9 cells. Int. J. Mol. Med. 24(6), 789-794 (2009).
118. Nohata N, Sone Y, Hanazawa T, et al. miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 2(1-2), 29-42 (2011).
119. Moriya Y, Nohata N, Kinoshita T et al. Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J. Hum. Genet. 57(1), 38-45 (2012).
120. Kawakami K, Enokida H, Chiyomaru T et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur. J. Cancer. 48(6), 827-836 (2012).